Table 2.

Overall activity of venetoclax in patients with AML

All N = 32 (%)IDH mutation N = 12 (%)
Objective response rate (CR + CRi) by IWG criteria6 (19)4 (33)
 CR2 (6)2 (17)
 CRia4 (13)2 (17)
Antileukemic activity that did not meet IWG criteria6 (19)2 (17)
 ≥50% bone marrow blast reduction with two cell line recovery and transfusion independenceb2 (6)0
 ≥50% bone marrow blast reduction with one cell line recoveryc2 (6)2 (17)
 ≥50% bone marrow blast reduction with no hematologic recovery2 (6)0
Treatment failured20 (63)6 (50)
Overall activitye12 (38)6 (50)
  • aOne with IDH mutation in exon 3; dose interruption for 20 days after week 4 and achieved CRi at week 24.

  • bOne with ≥50% bone marrow blast reduction at week 5 and recovery of hemoglobin and platelets, and one with ≥50% bone marrow blast reduction at week 12 and recovery of neutrophils and hemoglobin.

  • cBoth with ≥50% bone marrow blast reduction and recovery of a single cell line (hemoglobin).

  • dTreatment failure includes progressive disease and less than partial response by IWG criteria.

  • eOverall activity includes objective responses by IWG criteria and antileukemic activity that does not meet IWG criteria.